The positron emission tomography (PET) ligand [ 11 C]carfentanil is a selective agonist for m-opioid receptors and has been used for studying m-opioid receptors in the human brain. However, it is unknown if [ 11 C]carfentanil binding differentiates between subtype receptors m 1 and m 2 . In this study, we investigated whether m 1 and m 2 can be studied separately through receptor subtypeselective inhibition of [ 11 C]carfentanil by pharmacologic intervention. [ 11 C]Carfentanil binding characteristics on rat brain sections were assessed either alone or in the presence of the m-receptor inhibitor cyprodime or the m 1 -specific inhibitor naloxonazine.
T HE OPIOID RECEPTORS have been an important target for analgesics since the nineteenth century following the widespread use of morphine. They are mediators of the powerful analgesic effects by both endogenous opiate peptides and natural alkaloids (e.g., morphine) and synthetic analogues. The m-opioid receptors are of general interest as morphine and similar opioids with analgesic effects, such as oxycodone, have high affinity to this subtype. The m-opioid receptors can be further divided into subtypes, m 1 and m 2 , in addition to the recently discovered m 3 . 1 The m 1 -opioid receptor has been associated with the desired analgesic effect, whereas m 2 receptors mediate the unwanted side effects of morphine-based drugs, such as respiratory depression and reduced motility of the gastrointestinal tract. 2, 3 For this reason, it is imperative to understand the difference in pharmacology, structure, and biodistribution between these receptor subtypes.
Methodologies for studies of in vivo distribution and the pharmacokinetics/pharmacodynamics (PK/PD) of ligands interacting with the m 1 -and m 2 -opioid receptor subtypes are therefore of interest. The positron emission tomography (PET) ligand [ 11 C]carfentanil is a selective agonist for m-opioid receptors and has been used for studying all m-opioid receptor subtypes in aggregate in the human brain, 4 for example, during disease progression 5 and in states associated with drug dependency. 6 However, not much is known about whether [ 11 C]carfentanil binding differentiates between subtype receptors m 1 and m 2 .
Since the receptor binding of [ 11 C]carfentanil is reversible, it can be used to indirectly study the pharmacodynamics of mand potentially m 1 -or m 2 -selective agonists or antagonists in vivo by observing their displacement of [ 11 C] carfentanil in vivo. 7 In addition, important PK/PD parameters, such as the rate of onset of binding (k on ) and degree of receptor occupancy of unlabeled m-, m 1 -, or m 2 -selective compounds, can be quantified in the human brain.
In this study, we investigated whether the regional distributions of m 1 and m 2 could be studied separately through selective displacement of [ 11 C]carfentanil, both in vitro on rat brain sections and in the living rat brain by small animal PET/computed tomography (CT).
Method and Materials
Radiochemistry [ 11 C]Carfentanil was synthesized as described previously, 8 modified to the synthesis equipment at the PET Centre at Uppsala University Hospital.
Pharmaceuticals
Cyprodime (Tocris Biosciences, Bristol, UK) was used as a selective general m-opioid receptor antagonist. 9 A 5 mM stock solution was prepared by dissolving cyprodime in 30% hydroxypropyl-β-cyclodextrin (Kleptose, 300 mg/mL, Apoteket, Stockholm, Sweden).
Naloxonazine (Tocris Biosciences, Bristol, UK), a derivate of naloxone, is a selective antagonist to m 1 . 10 A 1 mM stock solution was prepared by dissolving naloxonazine in phosphate-buffered saline (NaCl 137 mM, KCl 2.7 mM, Na 2 HPO 4 10 mM, KH 2 PO 4 1.8 mM).
In Vitro Frozen Tissue Autoradiography
Freshly harvested rat brain (Sprague Dawley, male) was frozen to À80 C and processed into 20 mm sections by a microtome. To study tracer binding properties to the tissue, the sections were incubated in progressively higher concentrations (0À50 nM) of [ 11 C]carfentanil (n = 5 batches in total) in 50 mM TRIS + 0.5 mm ethylenediaminetetraacetic acid (EDTA) for 40 minutes at room temperature. Nonspecific binding was assessed by adding 40 mm of the general m-receptor antagonist cyprodime to the incubation buffer 10 minutes before tracer addition. Specific m 2 -receptor binding was assessed by instead adding 0.5 mm of naloxonazine, which selectively inhibits the m 1 receptor. The dose was kept relatively low (but still 500 times above the expected subnanomolar K d ) in order not to inadvertently inhibit other m-opioid receptors.
Tissue sections were then washed two times for 2.5 minutes in 50 mM TRIS + 0.5 mM EDTA at room temperature to remove excess tracer and then dried at 37 C for 5 minutes. The sections were then exposed against a phosphor-imager screen (Amersham Biosciences, Uppsala, Sweden) for 2 hours, digitalized using a PhosphorImager SI (Molecular Dynamics, Sunnyvale, CA), and analyzed using ImageQuant (Molecular Dynamics).
The data from all five experiments (two to three tracer concentrations in each experiment) were pooled, yielding 12 data points in total.
It was assumed that incubation with [ 11 C]carfentanil only resulted in total binding to each section, that is, both receptor-specific binding of the m 1 and m 2 receptors and nonspecific binding. Coincubation with cyprodime (which is a general m-receptor inhibitor) was assumed to block all m receptor-mediated [ 11 C]carfentanil binding, and the remaining binding thus represented nonspecific binding in each tissue. Finally, naloxonazine selectively inhibits m 1 ; thus, coincubation with [ 11 C]carfentanil will yield autoradiography images, which represent m 2 binding in aggregate with nonspecific binding.
For each tracer concentration, it is now possible to calculate the following: 
Calculation of binding to m 1 , m 2 , and both m receptors in aggregate was performed for each data point as described above and plotted against the added concentration of [ 11 C] carfentanil.
The tracer affinity (expressed as the dissociation constant K d ) for each receptor type and receptor density (B max ) was determined by nonlinear regression of receptor-specific binding using GraphPad Prism 5 (San Diego, CA). The K d was constrained to be shared between thalamus and cortex. The in vitro binding potential (BP) was calculated as the ratio B max /K d .
In Vivo PET
Sprague Dawley rats (male, n = 11, weight 338 ± 24 g) were housed under standard laboratory conditions with free access to food and water. All handling and experiments were carried out in accordance with national guidelines and were approved by the local ethics committee for animal research.
Anesthesia was induced by 3.0% isoflurane in 450 mL/min of 50% medical air/50% O 2 . The animal was placed on the heated bed of a Triumph Trimodality PET/single-photon emission computed tomography (SPECT)/CT system (Gamma Medica Inc, Northridge, CA) to prevent hypothermia, where continuous anesthesia was maintained by 1.5 to 2.0% isoflurane through a face mask. The breathing rate and body temperature were monitored by an integrated physiologic monitoring system. The animal was positioned with the intra-aural line in the center of the transaxial field of view.
[ 11 C]Carfentanil (n = 11, 6.2 ± 1.8 MBq corresponding to 0.08 ± 0.02 mg, or 0.24 ± 0.07 mg/kg of mass of carfentanil) in a maximum volume of 500 mL was administered as a singlebolus injection via a tail vein catheter, and the animal underwent a dynamic PET examination of the brain for 60 minutes in list mode, followed by a CT examination for 3 minutes (field of view = 8.0 cm).
The PET examinations were performed as baseline scans (n = 2), as displacement studies, or at different time points following intravenous pretreatment with one of two m-receptor antagonists (see Table 1 for details). Cyprodime (selective general m inhibitor, 3 mg/kg, n = 2) or naloxonazine (selective m 1 inhibitor, 1 mg/kg, n = 2) was thus administered 30 minutes following tracer injection to investigate the displacement of [ 11 C]carfentanil. Additionally, naloxonazine was administered 1.5 hours (n = 1), 6 hours (n = 2), or 24 hours (n = 2) prior to [ 11 C]carfentanil to investigate the time dependence on the blocking of m 1 . It has previously been shown that doses below 10 to 20 mg/kg naloxonazine intravenously in rats produce m 1 -selective binding in vivo. For the 1.5-to 24-hour time points, naloxonazine was administered under brief anesthesia (< 5 minutes). The animals were then allowed to wake up in each housing cage until being anesthetized again for the PET examination. Neither cyprodime (3 mg/kg) nor naloxonazine (1 mg/kg) induced any effects on animal physiology regarding temperature, breathing rate, or heart rate.
After the PET/CT examination, the animals were euthanized by an intravenous injection of 40 mg pentobarbital.
The PET data sets were reconstructed into 12 time frames (12 × 5 minutes) using a maximum likelihood expectation maximization (MLEM) three-dimensional algorithm (10 iterations) with corrections for scatter and random coincidences. The CT raw files were reconstructed using filtered backprojection and converted to DICOM. PET/CT data were analyzed using PMOD v3.13 (PMOD Technologies Ltd, Zurich, Switzerland). Volumes of interest were drawn manually on fused PET/CT images with support of a brain atlas to include thalamus, cortex, and cerebellum. [ 11 C]Carfentanil kinetics in thalamus, cortex, and cerebellum was expressed as standardized uptake values (SUVs), corrected for the amount of administered tracer (in MBq) and animal weight. Then uptake in the target tissues thalamus and cortex was expressed as a tissue to reference tissue ratio, using the cerebellum as the reference region being devoid of m receptorÀmediated binding. 11 The results on group levels are reported as means ± SEM.
Results

Radiochemistry
The radiochemical purity of [ 11 C]carfentanil (n = 9) was > 96%, and the specific radioactivity was between 7 and 111 GBq/mmol (on average, 45.8 GBq/mmol) at the end of synthesis.
In Vitro Frozen Tissue Autoradiography
High [ 11 C]carfentanil binding was found in brain regions with known high expression of m-opioid receptors such as thalamus, amygdala, cortex, and habenula (Figure 1 ). Coincubation with 40 mm cyprodime abolished all [ 11 C]carfentanil binding, showing that tracer binding was m receptor specific. Coincubation with 0.5 mm naloxonazine blocks only the m 1 -receptor subtype; subsequently, the [ 11 C]carfentanil binding in brain was almost, but not entirely, abolished. The remaining [ 11 C]carfentanil most likely consists of m 2 -mediated binding.
[ 11 C]Carfentanil exhibited saturable binding to m receptors (as assessed by cyprodime) in thalamus with a K d power of 10 above nanomolar (Figure 2 , AÀC, and Table 2 ). Binding in cortex was also saturable but with slightly lower B max (see Figure 2 , D and E, and Table 2 ).
The m 1 -specific binding of [ 11 C]carfentanil was calculated by subtracting m 2 -specific binding from the binding to all m receptors as described in detail above. [ 11 C]Carfentanil had lower affinity for m 2 compared to m 1 , displaying only partial saturation for receptor concentrations up to 40 nM (see Table 2 ). BP for m 2 was similar in thalamus and cortex. The BP in thalamus was 20.1 and 7.9 times higher for m 1 compared to m 2 in thalamus and cortex, respectively.
In Vivo PET
Tracer uptake (expressed as SUV) was highest in opioid receptorÀrich thalamus and low in cerebellum following administration of [ 11 C]carfentanil only ( Figure 3 , A and E). There was a strong displacement of [ 11 C]carfentanil in thalamus and, to a lesser extent, cortex, but not cerebellum, when cyprodime or naloxonazine was administered intravenously 30 minutes after tracer (Figure 3 , B, C, E, and F). This indicates that cerebellum is devoid of receptor-mediated [ 11 C]carfentanil binding and was therefore used as a reference region for further analysis. Each animal (total n = 11) was examined once by positron emission tomography. Displacement of [ 11 C]carfentanil from m 1 was investigated immediately after and 1.5, 6, and 24 hours following administration of naloxonazine. PET = positron emission tomography.
[ 11 C]Carfentanil accumulation in thalamus relative to cerebellum reached a plateau after 20 minutes, followed by slow washout especially after 40 minutes ( Figure 4A) . Administration of the m-blocking antagonist cyprodime 30 minutes into the PET examination showed a rapid decrease in retention in thalamus, corresponding to displacement of [ 11 C]carfentanil from available m receptors ( Figure 4B) . Naloxonazine, on the other hand, exhibited a slower onset of displacement of [ 11 C]carfentanil from m 1 receptors ( Figure 4C ) in thalamus. However, [ 11 C]carfentanil administration 1.5 hours after naloxonazine treatment displayed no appreciable binding in thalamus at all, > 95% reduction compared to baseline ( Figure 4D ). Six hours postadministration of naloxonazine, [ 11 C]carfentanil binding was reduced with approximately 50% compared to baseline, and binding was completely normalized after 24 hours (Figure 4, E and F) .
The uptake [ 11 C]carfentanil in cortex relative to cerebellum followed a similar pattern, but with lower magnitude of binding, approximately 50% compared to binding in thalamus ( Figure 5A ). Cyprodime exhibited rapid displacement of [ 11 C]carfentanil in contrast to naloxonazine ( Figure 5, B and C) . However, the binding of naloxonazine 1.5 hours postadministration completely inhibited [ 11 C] In vitro BP (calculated as the ratio B max /K d ), was higher for m 1 than for m 2 , indicating preferential binding to m 1 at tracer levels. In vitro BP was higher in thalamus than in cortex, consistent with the known higher expression of m-opioid receptors in thalamus. B max = total receptor density; BP = binding potential; K d = dissociation constant. carfentanil binding ( Figure 5D ). Similar to in thalamus, binding was increased at 6 hours and normalized 24 hours following naloxonazine administration ( Figure 5 , E and F).
Discussion
[ 11 C]Carfentanil has provided valuable insight into the understanding of human physiology at the m-receptor level relating to addiction to opiate drugs, 6 epilepsy, 5 and other phenomena, such as pain. 12 The complexity of the human opioid receptor systems has been progressively unraveled during the last decades, and what were collectively termed opioid receptors were subdivided into three opioid receptor subtypes: d, κ, and m. These were found to be closely related but to have distinctly different effects when activated by agonists or antagonized. Furthermore, as molecular biology has evolved, these subcategories have been further refined to include subtypes of each of the d, κ, and m receptors.
[ 11 C]Carfentanil was originally developed as a receptorspecific ligand for in vivo studies of the m-opioid receptor system in the human brain. 4 However, with increased understanding that the m-receptor subtypes 1 and 2 have specific distinctive roles in the regulation of analgesia and sedation, it becomes apparent that it is desirable to develop methodologies to image the receptor subtypes individually. No m 1 -or m 2 -selective radiolabeled ligands have yet been reported. Furthermore, the preferential binding of [ 11 C]carfentanil to either m-receptor subtype has not previously been examined. Therefore, we aimed to test if [ 11 C]carfentanil could be employed in this fashion in vivo by selectively inhibiting the m 1 receptor using naloxonazine.
Our in vitro autoradiography saturation binding results demonstrate that [ 11 C]carfentanil has a distinctly heterogeneous binding profile from m 1 -and m 2 -receptor subtypes. Binding to m 1 occurs with higher (> 100-fold) relative affinity than for m 2 . The apparent affinity to m receptors, which is just above the nanomolar range, thus consists of a mixture of very high affinity for m 1 and medium high affinity for m 2 . Similarly, BP for m 1 was more than 20 times higher than for m 2 in thalamus.
Additionally, we attempted to selectively image the m 1 and m 2 receptors in the living rat brain by employing a technique similar to the in vitro autoradiography study. Selective blocking of the m 1 receptors by naloxonazine should in theory leave only m 2 receptors for [ 11 C]carfentanil to interact with. However, we could only detect a slower displacement by using naloxonazine compared to cyprodime, and following 1.5 hours, no appreciable [ 11 C]carfentanil binding was detected. It is conceivable that the slower displacement could be attributed to the remaining binding of [ 11 C]carfentanil to m 2 receptors, but given that imaging at later time points revealed no m 2 binding above background, it is more likely that this effect is due to a more gradual onset of binding for naloxonazine compared to cyprodime. The difference in onset of binding could also be a consequence of the higher dose of cyprodime given (3 mg/kg) in comparison to that of naloxonazine (1 mg/kg).
The low or immeasurable in vivo binding of [ 11 C]carfentanil in the presence of naloxonazine likely reflects poorer affinity of [ 11 C]carfentanil to m 2 , based on the results from the in vitro autoradiography study. However, it could also be due to a lower abundance of m 2 receptors.
Given the large differences in in vitro BP (> 20-fold higher in thalamus), we interpret the in vivo results to mean that quantitative imaging of m 2 is not feasible even when selectively inhibiting available m 1 receptors.
We observe that weak but detectable binding of [ 11 C] carfentanil can be measured by autoradiography in thalamus also after blocking with naloxonazine (see Figure 1B) , which seems to conflict with the PET imaging results (see Figure 4D ). This islikelyduetothe lowersensitivity(orlargererrorbars)ofthe imaging technique compared to the autoradiography technique.
The findings reported here are of interest if the results are translatable to the human situation because this means that previous and future clinical studies employing [ 11 C]carfentanil will be biased to measure m 1 rather than m 2 .
Acknowledgment
Ram Kumar Selvaraju, Veronika Asplund, and Beatrice Borg are acknowledged for excellent technical assistance.
Financial disclosure of authors and reviewers: None reported. 
